Protein Ingestion and Skeletal Muscle Atrophy

Muscle Atrophy Clinical Trial

Official title:

Understanding the Role of Protein Ingestion on Skeletal Muscle Atrophy During an Acute Period of Disuse

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03797781
• Other study ID #: 6500619582
• Status: Completed
• Phase: N/A
• Start date: October 31, 2017
• Est. completion date: December 31, 2019

Study information

• Verified date: September 2020
• Source: University of Exeter
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The effect of different protein intakes on skeletal muscle atrophy during short term unilateral leg immobilisation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: December 31, 2019
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• BMI >18 and <28 no prescription medications or current illness.

Exclusion Criteria:

• BMI <18 and >28 current prescription medication no history of leg injury.

• Smoker

• Medical conditions including (cardiovascular disease ((e.g. hypertension)), metabolic disease ((e.g. type 2 diabetes)), any personal or family history of deep vein thrombosis.

Related Conditions & MeSH terms

• Atrophy
• Muscle Atrophy
• Muscular Atrophy

Intervention

Other:
• Lower limb immobilisation (leg brace) with varying levels of protein intake
Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake

Locations

Country	Name	City	State
United Kingdom	Sport and Health Science	Exeter	Devon

Sponsors (1)

Lead Sponsor	Collaborator
University of Exeter

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Muscle size		3 days
Secondary	Muscle strength		3 days